Intec Pharma Gets Michael Fox Grant

Intec Pharma has received a grant from The Michael J. Fox Foundation for Parkinson’s Research in the amount of $705,000. The grant will finance a pre-clinical safety trial using the company’s delayed release Accordion Pill Carbidopa/Levodopa developed for the treatment of Parkinson’s disease. Intec Pharma has completed successfully Phase II clinical studies in approximately 60 patients. In 2010, Intec performed a 3 month trial in pre-clinical models in which the safety of the Accordion platform was proven. Since the AP-CD/LD is intended for a twice a day dosing regimen on a long term basis (for many years), Intec will perform a longer trial using the AP-CD/LD. The Trial is expected to be completed during the first quarter of 2014.

Written by

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam libero diam, elementum eget porttitor at, tincidunt at nulla.